Safety and Efficacy of Cangrelor in Acute Stroke Treated with Mechanical Thrombectomy: Endovascular Treatment of Ischemic Stroke Registry and Meta-analysis.


Journal

AJNR. American journal of neuroradiology
ISSN: 1936-959X
Titre abrégé: AJNR Am J Neuroradiol
Pays: United States
ID NLM: 8003708

Informations de publication

Date de publication:
03 2022
Historique:
received: 21 10 2021
accepted: 23 12 2021
pubmed: 5 3 2022
medline: 28 4 2022
entrez: 4 3 2022
Statut: ppublish

Résumé

Rescue therapies are increasingly used in the setting of endovascular therapy for large-vessel occlusion strokes. Among these, cangrelor, a new P2Y12 inhibitor, offers promising pharmacologic properties to join the reperfusion strategies in acute stroke. We assessed the safety and efficacy profiles of cangrelor combined with endovascular therapy in patients with large-vessel-occlusion stroke. We performed a retrospective patient data analysis in the ongoing prospective multicenter observational Endovascular Treatment in Ischemic Stroke Registry in France from July 2018 to December 2020 and conducted a systematic review and meta-analysis using several data bases. Indications for cangrelor administration were rescue strategy in case of refractory intracranial occlusion with or without intracranial rescue stent placement, and cervical carotid artery stent placement in case of cervical occlusion (tandem occlusion or isolated cervical carotid occlusion). In the clinical registry, 44 patients were included (median initial NIHSS score, 12; prior intravenous thrombolysis, 29.5%). Intracranial stent placement was performed in 54.5% ( Cangrelor offers promising safety and efficacy profiles, especially considering the complex endovascular reperfusion procedures in which it is usually applied. Further large prospective data are required to confirm these findings.

Sections du résumé

BACKGROUND AND PURPOSE
Rescue therapies are increasingly used in the setting of endovascular therapy for large-vessel occlusion strokes. Among these, cangrelor, a new P2Y12 inhibitor, offers promising pharmacologic properties to join the reperfusion strategies in acute stroke. We assessed the safety and efficacy profiles of cangrelor combined with endovascular therapy in patients with large-vessel-occlusion stroke.
MATERIALS AND METHODS
We performed a retrospective patient data analysis in the ongoing prospective multicenter observational Endovascular Treatment in Ischemic Stroke Registry in France from July 2018 to December 2020 and conducted a systematic review and meta-analysis using several data bases. Indications for cangrelor administration were rescue strategy in case of refractory intracranial occlusion with or without intracranial rescue stent placement, and cervical carotid artery stent placement in case of cervical occlusion (tandem occlusion or isolated cervical carotid occlusion).
RESULTS
In the clinical registry, 44 patients were included (median initial NIHSS score, 12; prior intravenous thrombolysis, 29.5%). Intracranial stent placement was performed in 54.5% (
CONCLUSIONS
Cangrelor offers promising safety and efficacy profiles, especially considering the complex endovascular reperfusion procedures in which it is usually applied. Further large prospective data are required to confirm these findings.

Identifiants

pubmed: 35241418
pii: ajnr.A7430
doi: 10.3174/ajnr.A7430
pmc: PMC8910798
doi:

Substances chimiques

Adenosine Monophosphate 415SHH325A
cangrelor 6AQ1Y404U7

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

410-415

Informations de copyright

© 2022 by American Journal of Neuroradiology.

Références

Neuroradiology. 2021 Jun;63(6):925-934
pubmed: 33174182
Front Neurol. 2021 Jun 04;12:636682
pubmed: 34149590
AJNR Am J Neuroradiol. 2021 Aug;42(8):1452-1457
pubmed: 34117019
Clin Neuroradiol. 2019 Sep;29(3):401-414
pubmed: 30895349
Stroke. 2016 Sep;47(9):2360-3
pubmed: 27444259
Stroke. 2017 May;48(5):1203-1209
pubmed: 28373302
Clin Neuroradiol. 2020 Sep;30(3):453-461
pubmed: 31309241
J Neurointerv Surg. 2019 Apr;11(4):347-351
pubmed: 30552167
J Stroke Cerebrovasc Dis. 2021 Feb;30(2):105521
pubmed: 33310073
J Neurointerv Surg. 2018 Aug;10(8):746-750
pubmed: 29203731
J Neurointerv Surg. 2020 Mar;12(3):271-273
pubmed: 31530654
Stroke. 2019 Sep;50(9):2364-2370
pubmed: 31670928
Stroke. 2020 Oct;51(10):2925-2933
pubmed: 32933416
Interv Neuroradiol. 2021 Dec;27(6):837-842
pubmed: 33945341
Interv Neuroradiol. 2021 Feb;27(1):88-98
pubmed: 32611215
Pharmacotherapy. 2021 Oct;41(10):811-819
pubmed: 34496076
Clin Neuroradiol. 2021 Jun;31(2):439-448
pubmed: 32382875
Cardiol Rev. 2017 May/Jun;25(3):133-139
pubmed: 28379902
Stroke. 2019 Jun;50(6):1460-1466
pubmed: 31084327
J Stroke. 2017 May;19(2):131-142
pubmed: 28592777
AJNR Am J Neuroradiol. 2021 Jul;42(7):1258-1263
pubmed: 33888454
World Neurosurg. 2019 Dec;132:e235-e245
pubmed: 31493593
AJNR Am J Neuroradiol. 2018 Oct;39(10):1848-1853
pubmed: 30166434
Stroke. 2018 Apr;49(4):958-964
pubmed: 29581342
J Neurointerv Surg. 2021 Jan;13(1):30-32
pubmed: 32414891
AJNR Am J Neuroradiol. 2020 Nov;41(11):2094-2099
pubmed: 33033047
Br J Anaesth. 2019 Jul;123(1):e2-e5
pubmed: 31010645
Lancet. 2016 Apr 23;387(10029):1723-31
pubmed: 26898852
Neuroradiology. 2020 May;62(5):629-637
pubmed: 31927615

Auteurs

G Marnat (G)

From the Department of Diagnostic and Interventional Neuroradiology (G.M., F.G.), University Hospital of Bordeaux, Bordeaux, France gaultier.marnat@chu-bordeaux.fr.

S Finistis (S)

Aristotle University of Thessaloniki (S.F.), AhepaHospital, Thessaloniki, Greece.

F Delvoye (F)

Department of Interventional Neuroradiology (F.D., J.-P.D., M.M.), Rothschild Foundation, Paris, France.

I Sibon (I)

Department of Neurology (I.S.), Stroke Center, University Hospital of Bordeaux, Bordeaux, France.

J-P Desilles (JP)

Department of Interventional Neuroradiology (F.D., J.-P.D., M.M.), Rothschild Foundation, Paris, France.

M Mazighi (M)

Department of Interventional Neuroradiology (F.D., J.-P.D., M.M.), Rothschild Foundation, Paris, France.

F Gariel (F)

From the Department of Diagnostic and Interventional Neuroradiology (G.M., F.G.), University Hospital of Bordeaux, Bordeaux, France.

A Consoli (A)

Department of Diagnostic and Interventional Neuroradiology (A.C.), Foch Hospital, Versailles Saint-Quentin en Yvelines University, Suresnes, France.

C Rosso (C)

Department of Neurology (C.R.).

F Clarençon (F)

Neuroradiology (F.C., M.E.), Centre Hospitalier Universitaire Pitié Salpétrière Hospital, Paris, France.

M Elhorany (M)

Neuroradiology (F.C., M.E.), Centre Hospitalier Universitaire Pitié Salpétrière Hospital, Paris, France.

C Denier (C)

Department of Neurology (C. Denier).

V Chalumeau (V)

Neuroradiolology (V.C., J.C.) Centre Hospitalier Universitaire Kremlin Bicêtre, Le Kremlin Bicêtre, France.

J Caroff (J)

Neuroradiolology (V.C., J.C.) Centre Hospitalier Universitaire Kremlin Bicêtre, Le Kremlin Bicêtre, France.

L Veunac (L)

Neuroradiolology (L.V.), Centre Hospitalier Cõte Basque, Bayonne, France.

F Bourdain (F)

Department of Neurology (F.B.).

J Darcourt (J)

Neuroradiolology (J.D.), Centre Hospitalier Universitaire de Toulouse, Toulouse, France.

J-M Olivot (JM)

Departments of Neurology (J.-M.O.).

R Bourcier (R)

Department of Neuroradiology (R.B.), University Hospital of Nantes, Nantes, France.

C Dargazanli (C)

Departments of Interventional Neuroradiology (C. Dargazanli).

C Arquizan (C)

Neurology (C.A.), Centre Hospitalier Regional Universitaire Gui de Chauliac, Montpellier, France.

S Richard (S)

Department of Neurology (S.R.), Université de Lorraine, Centre Hospitalier Regional Universitaire Nancy, Nancy, France.

B Lapergue (B)

Department of Neurology (B.L.), Foch Hospital, Versailles Saint-Quentin en Yvelines University, Suresnes, France.

B Gory (B)

Department of Diagnostic and Therapeutic Neuroradiology (B.G.), Université de Lorraine, Centre Hospitalier Regional Universitaire Nancy, Nancy, France.
Université de Lorraine (B.G.), Imagerie Adaptative Diagnostique et Interventionnelle, Institut National de la Santé et de la Recherche Médicale U1254, Nancy, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH